Core Viewpoint - The strategic partnership between Haizheng Pharmaceutical and Aixin Dawei marks a significant advancement in the development of innovative cancer therapies, particularly with the introduction of the first-in-class small molecule drug HSE-001 (AST-3424) in China [1][2]. Group 1: Partnership and Drug Development - Haizheng Pharmaceutical has secured exclusive rights for the research, registration, production, and commercialization of HSE-001 (AST-3424) in China, including Hong Kong and Macau [1]. - The agreement includes an upfront payment to Aixin Dawei, along with tiered royalties based on net sales and milestone payments [1]. - HSE-001 (AST-3424) is noted as Haizheng's first innovative drug with potential first-in-class characteristics, representing a key breakthrough in the company's dual-driven innovation strategy [1]. Group 2: Company Strategies and Goals - Haizheng Pharmaceutical's chairman emphasized that the introduction of HSE-001 signifies a new starting point and injects new momentum into the company's research and development efforts, maintaining a strategic focus on innovative drug development [2]. - The company aims to solidify its industrial foundation while optimizing traditional business and expanding into new therapeutic areas, particularly in cardiovascular metabolism and oncology [2]. - Aixin Dawei's founder highlighted that this collaboration is a significant milestone for the company, aiming to expedite the availability of innovative drugs for patients in China and globally [2].

Core Viewpoint - Haizheng Pharmaceutical has announced a collaboration with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. to introduce the targeted small molecule conjugate drug HSE-001 (AST-3424) in specific regions, marking its first potential First-in-Class (FIC) small molecule conjugate drug [1] Group 1 - Haizheng Pharmaceutical will acquire the rights to HSE-001 (AST-3424) across mainland China, Hong Kong, and Macau [1] - The collaboration includes the development of additional new drugs based on the AKR1C3 enzyme-activated targeted small molecule conjugate (SMDC) technology platform [1]